Filing Flows › Vistagen Therapeutics (VTGN) › Stock forecast & fair value
Vistagen Therapeutics (VTGN) stock forecast and price target
Vistagen Therapeutics (VTGN) trades at $0.16. The analysts' price target is $1.00 (+511%).
Vistagen Therapeutics' latest quarter
Vistagen Therapeutics, Q1 FY27: revenue $1.5M (+505% year over year), operating margin -904.3%, net loss $13.0M, operating cash flow −$14.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for VTGN stock?
The analysts' 12-month target is $1.00, +511% from $0.16. The average rating is none.
Does Vistagen Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 50% of the quarters on record.
Is VTGN stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.